CD44 and inflammatory breast carcinoma: Researchers led by Polyak et al. [17,18] showed that samples from IBC patients were enriched in CD44+/CD24− CSCs and activated phosphor-STAT3 (pSTAT3) cells, and 40% of CD44+/CD24− cells were positive for pSTAT3, suggesting STAT pathway activation in IBC CSCs.